

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		107531504	
STATEMENT BY APPLICANT			
<i>(use as many sheets as necessary)</i>			
Sheet	1	of	2
		Attorney Docket Number 21245YP	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature /Sahar Javanmard/ Date Considered 12/03/2007

**Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for Form 1449B/PTO 
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMBINED IF KNOWN	
Application Number	10/531504
Filing Date	March 11, 2005
First Named Inventor	John J. Renger et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	21245YP

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/S.J./		Santi, C. et al. Differential Inhibition of T-Type Calcium Channels by Neuroleptics. <u>Journal Neuroscience</u> . 15 January 2002, vol. 22, No. 2, pages 396-403.
/S.J./		Massie, B.M. Mibepradil a T-Type Channel-Selective Calcium Antagonist: Clinical Trials in Chronic Stable Angina Pectoris. <u>American Journal of Hypertension</u> . April 1998, vol 11, No. 4, pages 95S-102S.

Examiner Signature	/Sahar Javanmard/	Date Considered	12/03/2007
--------------------	-------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 09/02/2003